G protein-coupled receptor 17 (GPR17) was recently reported to be a Foxo1 target in agouti-related peptide (AGRP) neurons. Intracerebroventricular injection of GPR17 agonists induced food intake, whereas administration of an antagonist to the receptor reduced feeding. These data lead to the conclusion that pharmacological modulation of GPR17 has therapeutic potential to treat obesity. Here we report that mice deficient in Gpr17 (Gpr17 −/− ) have similar food intake and body weight compared with their wild-type littermates. Gpr17 −/− mice have normal hypothalamic Agrp mRNA expression, AGRP plasma levels, and metabolic rate. GPR17 deficiency in mice did not affect glucose homeostasis or prevent fat-induced insulin resistance. These data do not support a role for GPR17 in the control of food intake, body weight, or glycemic control.
GPR17 | AGRP | diabetes | body weight | food intake H ypothalamic neurons expressing agouti-related peptide (AGRP) play an important role in feeding (1) (2) (3) . AGRP acts as an inverse agonist on melanocortin 4 receptors (4, 5) . Leptin and insulin are anorectic hormones, which partly regulate food intake and energy homeostasis by inhibiting AGRP neurons (6) (7) (8) . The transcription factor Foxo1 is expressed in AGRP neurons and represents a shared mediator of the pathways activated by insulin and leptin to suppress food intake (9, 10) . Accordingly, Foxo1 expression is reduced by insulin and leptin and these hormones' effect on feeding is inhibited following hypothalamic Foxo1 overexpression (9) . Moreover, activation of Foxo1 in the hypothalamus increases food intake and body weight, whereas inhibition of Foxo1 decreases both (9) . Finally, ablation of Foxo1 in AGRP neurons results in reduced food intake, leanness, and improved glycemic control (11) .
The G protein-coupled receptor, GPR17, is a prominent Foxo1 target and highly expressed in AGRP neurons (11) . GPR17 is phylogenetically related to nucleotide P2Y and cysteinyl-leukotriene receptors (12) . It has been reported that uridyl-diphosphate glucose (UDP glucose) and leukotriene D4 (LTD4) activate GPR17, whereas the P2Y12 antagonist, Cangrelor, suppresses receptor activity (13) . Consistent with these findings, intracerebroventricular injection of UDP glucose and LTD4 in mice stimulated food intake, whereas administration of Cangrelor suppressed it (11) . However, other studies have failed to demonstrate activation of GPR17 with UDP glucose and LTD4 (14, 15) . In this study, we generated and fed Gpr17-deficient (Gpr17 −/− ) mice a normal and a high-fat diet (HFD). Under these experimental conditions, we did not observe an effect of GPR17 on food intake, body weight, or glycemic control. These data call into question the therapeutic potential of inhibiting GPR17 to treat obesity and related metabolic disorders.
Results
Reporter Gene Expression from the Gpr17 Locus and AGRP Plasma Levels in Gpr17 −/− and Wild-Type Mice. Gpr17 −/− mice were developed by homologous recombination using Regeneron's VelociGene technology. The murine Gpr17 gene [National Center for Biotechnology Information (NCBI) Reference Sequence: NM_001025381.2] is a single exon contained entirely within the coding region of the Lims2 gene (NCBI Reference Sequence: NM_144862.3), albeit on the opposite strand. We deleted a 1,032-bp segment with the lacZ fused in frame just after Gpr17's ATG without deleting any exons from Lims2 (Fig. 1A) . No Gpr17 mRNA was detected in the hypothalamus of knockout (KO) animals (Fig. 1B) . Lims2 expression was reduced by 29% in Gpr17 −/− mice (Fig. 1B) . Gpr17 −/− mice were born in the expected Mendelian ratios. Reporter expression was found in multiple areas of the brain and the hypothalamus (Fig.  1C) , consistent with a previous report (16) . Gpr17 is expressed in few peripheral tissues at lower levels than in the hypothalamus (Fig.  1D ). Gpr17
−/− and wild-type mice had similar levels of hypothalamic Agrp mRNA and circulating AGRP in the fasted state ( Fig. 1 B and E). Refeeding of Gpr17 −/− and control mice produced an equivalent decrement in the AGRP plasma levels (Fig. 1E ).
Gpr17
−/− Mice Have Normal Food Intake, Body Weight, and Metabolic
Rate. Mice lacking GPR17 had normal body weight compared with their wild-type littermates ( Fig. 2A) . Consistent with this data, there were no differences in the light and dark phases of the light cycle in food intake (Fig. 2B) or energy expenditure (Fig. 2C ). Data for oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), respiratory quotient (RER), energy expenditure, and food intake in the light and dark phases of the light cycle are shown in Fig. S1 A-E. Locomotor activity was similar between both groups of mice ( Fig. 2D and Fig. S1F ). Gpr17
and wild-type mice fed a HFD for 10 wk had a 70% increase in body weight, but showed no difference in food intake or energy expenditure (Fig. 2 E-G and Fig. S1 G-K). There were no significant differences in body weight between the KO mice and controls at any time point over the first 9 wk of high-fat feeding. Locomotor activity was slightly reduced in HFD mice ( Fig. 2H and Fig. S1L ). No genotypic differences in body composition
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The authors declare no conflict of interest. were observed in mice on standard chow or HFD, except the Gpr17 −/− mice on the chow diet tended to have higher body fat content (Table 1) . Hypothalamic Gpr17 and Agrp mRNA expression did not change in response to high-fat feeding (Fig.  S2A ). AGRP plasma levels were similar between Gpr17 −/− and wild-type mice fed a HFD (Fig. S2B) . These data suggest that ablation of GPR17 does not affect food intake or body weight in mice.
Gpr17
−/− Mice Have Normal Glucose Homeostasis and Insulin Sensitivity.
−/− mice had normal glycemic control as revealed by an oral glucose tolerance test (oGTT) (Fig. 3A) or insulin tolerance test (ITT) (Fig. 3B ) compared with wild-type mice. Feeding Gpr17 −/− and wild-type mice a HFD for 10 wk impaired glucose tolerance (Fig. 3A) and insulin sensitivity (Fig. 3B) . No genotypic differences in glucose or insulin tolerance were observed in mice on normal chow or HFD. These data show that GPR17 does not control glucose homeostasis or protect from glucose intolerance in response to a HFD.
Discussion
The main findings of the present study are that (i) ablation of GPR17 does not regulate circulating AGRP levels, food intake, metabolic rate, and body weight and (ii) GPR17 does not control glucose homeostasis or prevent high-fat-induced insulin resistance.
GPR17 is abundantly expressed in AGRP neurons and was recently suggested to control feeding using pharmacological modulators of the receptor and intracerebroventricular administration in mice (11) . However, these compounds have subsequently been questioned as pharmacological modulators of GPR17 (14, 15) . In this study, we confirm that Gpr17 is highly expressed in the hypothalamus of mice. However, wild-type and Gpr17 −/− mice show no differences in food intake or metabolic rate and can mount a significant and similar increase in body weight in response to high-fat feeding. Gpr17 −/− mice have normal Agrp hypothalamic mRNA expression and circulating AGRP levels.
The Gpr17 gene is contained entirely within the coding region of the Lims2 gene, but on the opposite strand. LIMS2 belongs to the family of focal adhesion proteins and functions as a component of the integrin signaling pathway (17) . The small but significant reduction in Lims2 mRNA expression is unlikely to affect the metabolism of Gpr17 −/− mice because Lims2-deficient mice do not have an apparent phenotype (18) and Agrp expression was similar in Gpr17 −/− and wild-type mice. β-Galactosidase (lacZ) staining of GPR17 in the brain showed widespread expression, suggesting that the receptor has a more general function rather than a specific role in AGRP neurons. Previous studies have shown that GPR17 is expressed in oligodendrocyte precursors (19) and negatively regulated by the oligodendrocyte maturation transcription factor, Olig1 (20) . Whereas ablation of GPR17 in mice caused only a slight advance in central nervous system (CNS) myelination, overexpression of GPR17 inhibited myelinogenesis within the CNS of mice (16) , suggesting it plays a role not just in development of the CNS, but could also negatively impact the adult nervous system following traumatic injury. Consistent with this data, knockdown of Gpr17 mRNA levels in a focal ischemia rat model attenuated shortterm neuron loss, brain atrophy, and microglial activation after reperfusion (21) . Thus, GPR17 seems to control oligodendrocyte function rather than AGRP neuronal activity.
The Agrp-Foxo1 −/− mice (which have low Gpr17 expression) exhibit reduced hepatic glucose production and improved glucose homeostasis (11) . Here we demonstrate a lack of involvement of GPR17 in the regulation of glucose control. Moreover, Gpr17 −/− mice are not protected from HFD-induced insulin resistance. The nature of the Foxo1 target gene(s) mediating the beneficial effects on food intake and glycemic control in the Agrp-Foxo1 −/− mice remains unknown.
In conclusion, the present data do not support a role for GPR17 in the regulation of food intake or glucose homeostasis. Thus, GPR17 does not appear to be a viable therapeutic target for the treatment of obesity and type 2 diabetes.
Materials and Methods

Animals. Gpr17
−/− mice (100% C57BL/6NTac background) were generated by homologous recombination using Regeneron's VelociGene technology (22) . Body composition was measured using μCT in Gpr17 −/− (KO) and wild-type (WT) mice on chow diet (13 wk of age) and following 10 wk of high-fat feeding. All groups had eight animals. Values are mean ± SEM. *P < 0.05.
VelociGene allele identification number is VG12229. Male mice were used throughout this study and housed four to five per cage in a controlled environment (12-h light/dark cycle, 23 ± 1°C, 60-70% humidity) and fed ad libitum with standard chow (Purina Laboratory Rodent Diet 5001, LabDiet). Some mice were fed a high-fat diet (Research Diets, D12492; 60% fat by calories). In the food intake, body weight, metabolic rate, and glucose studies, comparisons were made between wild-type and knockout littermates. C57BL/6 mice (males; Taconic) were used for Gpr17 expression studies. All animal procedures were conducted in compliance with protocols approved by the Regeneron Pharmaceuticals Institutional Animal Care and Use Committee.
Glucose Homeostasis Measurements. For the insulin tolerance test, mice (male; 10 wk of age) were fasted for 4 h before testing. The fast started at 9:00 AM, 2 h after initiation of the light cycle. Fasting glucose was measured via tail bleed using the Accu-Chek Compact Plus (Roche Diagnostics). Insulin stock was prepared from Humulin R (Lilly). Mice on normal chow were injected i.p. with 0.75 units insulin/kg body weight. Mice on the HFD (male; 23 wk of age; subjected to high-fat feeding for 10 wk) were injected i.p. with 2.0 units insulin/kg body weight. Blood glucose was measured with the glucometer via tail bleed at 0, 15, 30, 60, and 120 min postinjection. For the oral glucose tolerance test, mice were fasted overnight (16 h) followed by oral gavage of glucose at 2 g/kg body weight. The fast started at 5:00 PM, 2 h before initiation of the dark cycle. Blood glucose level was evaluated at 0, 15, 30, 60, and 120 min postinjection.
Body Composition Assessments. MicroCT (μCT) measurements were performed using the Quantum FX micro CT preclinical in vivo imaging system (Caliper Life Sciences). Mice (male) fed the chow diet were 13 wk of age at time of μCT; mice (male) fed the HFD were 24 wk of age at time of μCT and on the HFD for the last 11 wk. Mice were anesthetized using Forane (Baxter). Scans were performed using field of view setting = 60 and scan technique = Dyn17Sec2. Data conversion was performed using the Caliper analysis software (Caliper Life Sciences). Hypothalamic Gene Expression. Hypothalamus was dissected from whole brain using an acrylic mouse brain block (Harvard Apparatus), placed in RNAlater (Qiagen), and homogenized in a Precellys mill using the Precellys Ceramic kit 1.4/2.8 mm (Peqlab). Total RNA was isolated with the RNeasy Fibrous Tissue Mini kit (Qiagen), including DNase I digestion and quantified with the Quant-iT RiboGreen RNA assay (Life Technologies). Reverse transcription to cDNA was done using the BioRad iScript cDNA synthesis kit. Gpr17, Agrp, and Lims2 cDNA were quantified with the digital droplet PCR method (23) using the ddPCR Supermix for probes (no UDP) kit on a QX-200 system (BioRad). TaqMan primer-probe sets are available upon request.
LacZ Staining. LacZ histochemistry was performed as described earlier (24) . Slides were scanned on Aperio ScanScope AT Turbo (Leica) and annotated with Aperio 5ImageScope.
Plasma AGRP Measurements. The concentration of circulating AGRP was measured in mouse EDTA plasma using the mouse AGRP fluorescent immunoassay kit from Phoenix Pharmaceuticals, according to the manufacturer's instructions. Signal calibration was done based on a standard curve obtained with known AGRP concentrations between 10 and 1,000 pg/mL.
Data Analysis. All data are expressed as mean ± SEM. Two-way ANOVA with Bonferroni's post hoc analysis was performed on data collected for hypothalamic gene expression, ITT, oGTT, and metabolic cage studies. Unpaired Student's t test was used to analyze data collected from the μCT and serum chemistry studies. All analysis was performed using GraphPad PRISM 6.0e (GraphPad Software). 
